Gilead (GILD) previously reported that data from the PURPOSE 2 study showed lenacapavir reduced HIV infections by 96% ...

PrEP uptake in MSM who inject drugs is low, although research shows this group is at higher risk for HIV acquisition through ...

PrEP is medicine taken by HIV-negative people to avoid contracting the virus. “The increasing availability of stimulant drugs ...

Data from the Centers for Disease Control and Prevention released Tuesday shows meaningful declines in STI rates between 2022 ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Margareth Mwakilasa, an assistant research fellow at Muhimbili University of Health and Allied Sciences in Tanzania and a PhD student in Global Health at University College Dublin, presented her ...

consider speaking with a healthcare professional about preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP).

A University of New Mexico researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing from the Diné Nation, Crystal Lee has been researching ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...